Skip to main content
HCPCS Q5119 · Level II · Part B drug

Q5119: rituximab-pvvr (Ruxience), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q5119

Billing unit
10 MG
Inj ruxience, 10 mg
ASP payment limit
$5.792
October 2026; -64.2% vs July 2026
Practitioner MUE
150
MAI 3
OPPS status
SI K
APC 9367
NCCI exposure
no PTP pairs
Coverage articles
4
15 states

TL;DR

HCPCS Q5119 is the Level II code for Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg, billed per 10 MG. The Medicare Part B ASP payment limit for October 2026 is $5.792 per billing unit, down 64.2% from July 2026. The practitioner MUE allows up to 150 units per date of service (MAI 3), so a full 150-unit day is $868.80 at the current limit. Under OPPS it carries status indicator K in APC 9367. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. The 10 mg billing unit means doses are reported in multiples of ten milligrams, with any remainder rounded per contractor policy; mismatched units against the NDC quantity trigger MUE and NDC-unit edits. Other HCPCS codes whose descriptor names rituximab: Q5115 (biosimilar rituximab-abbs (Truxima) from Cephalon, LLC); Q5123 (biosimilar rituximab-arrx (Riabni) from Amgen Inc); J9312 (non-biosimilar rituximab (Rituxan) from Genentech, Inc). The ASP crosswalk maps 2 NDCs to it, sold as Ruxience by Pfizer Inc. 4 Medicare coverage articles list the code across 15 states, including A55639.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q5119 at $5.792 per 10 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $16.16 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q5119
QuarterPayment limitPerCoinsurance
October 2026$5.79210 MG20%
July 2026$16.1610 MG—
CMS note: AMP-based payment limit

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to Q5119. Report the NDC in the claim's drug segment and bill the number of Q5119 units that equals the quantity administered divided by 10 MG; the last column gives units per full package.

NDCs that crosswalk to Q5119
NDCDrug nameLabelerPackage sizeBilling units / package
00069-0238-01RuxiencePfizer Inc10 × 110
00069-0249-01RuxiencePfizer Inc50 × 150

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for Q5119. For practitioners the limit is 150 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for Q5119 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services1503 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital1503 Date of Service Edit: ClinicalPrescribing Information

MUE for Q5119 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q5119 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q5119 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q5119 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

4 current Medicare Administrative Contractor articles list Q5119 in their HCPCS tables, covering 15 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing Q5119
ArticleTitleContractor(s)StatesRelated LCD
A55639Billing and Coding: Chemotherapy Agents for Non-Oncologic ConditionsWisconsin Physicians Service Insurance CorporationIA KS MO NEL37205
A56380Billing and Coding: RituximabPalmetto GBANC SC VA WVL35026
A58582Billing and Coding: Off-label Use of Rituximab and Rituximab BiosimilarsCGS Administrators, LLCKY OHL38920
A59101Billing and Coding: Off-label Use of Rituximab and Rituximab BiosimilarsWellpoint FederalCT IL MN NY WIL39297

Diagnoses Medicare contractors cover for Q5119

4 billing and coding articles attach a covered diagnosis list to Q5119: 945 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for Q5119
ICD-10-CMDescription (FY2027)Articles covering
D59.0Drug-induced autoimmune hemolytic anemia4 of 4
D59.11Warm autoimmune hemolytic anemia4 of 4
D59.12Cold autoimmune hemolytic anemia4 of 4
D59.13Mixed type autoimmune hemolytic anemia4 of 4
D69.3Immune thrombocytopenic purpura4 of 4
D69.41Evans syndrome4 of 4
G35.ARelapsing-remitting multiple sclerosis4 of 4
G36.0Neuromyelitis optica [Devic]4 of 4
G70.00Myasthenia gravis without (acute) exacerbation4 of 4
G70.01Myasthenia gravis with (acute) exacerbation4 of 4
L12.0Bullous pemphigoid4 of 4
M33.12Other dermatomyositis with myopathy4 of 4
M33.22Polymyositis with myopathy4 of 4
N04.0Nephrotic syndrome with minor glomerular abnormality4 of 4
M31.11Hematopoietic stem cell transplantation-associated thrombotic microangiopathy [HSCT-TMA]4 of 4
930 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to Q5119 are counted here: a group whose instructions name Q5119, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to Q5119, by article
ArticleContractorGroups that applyCovered codes for Q5119Full list
A55639Wisconsin Physicians Service Insurance Corporation6 groups apply to Q5119309On LCD L37205
A56380Palmetto GBAgroups 1 and 2 apply to Q5119692On LCD L35026
A58582CGS Administrators, LLCone list for every code in the article49On LCD L38920
A59101Wellpoint Federalone list for every code in the article836On LCD L39297

Local coverage policies that list Q5119

4 active Local Coverage Determinations list Q5119 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q5119 carries status indicator K and is assigned to APC 9367, with a published national unadjusted payment of $5.792. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q5119 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $5.79 per 10 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q5119 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q5119

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q5119

What does HCPCS code Q5119 describe?

Q5119 is defined by CMS as "Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg". Each billing unit represents 10 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q5119 a CPT code?

No. Q5119 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as rituximab-pvvr (Ruxience); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q5119 reports the drug itself in 10 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q5119 in October 2026?

The ASP-based payment limit is $5.792 per 10 MG, with 20% beneficiary coinsurance. The July 2026 limit was $16.16. Commercial payers use their own fee schedules.

How many units of Q5119 can be billed per day?

The practitioner Medically Unlikely Edit is 150 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to Q5119?

The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Ruxience (Pfizer Inc). For example NDC 00069-0238-01 (package size 10) equals 10 billing units of Q5119.

Does Q5119 have NCCI bundling edits?

No active practitioner PTP pairs list Q5119 as a column-1 or column-2 code in the v323r0 release.

Q5119 vs Q5115: what is the difference?

Both are HCPCS Level II codes whose descriptor names rituximab. What sets Q5115 apart: biosimilar rituximab-abbs (Truxima) from Cephalon, LLC. Q5119 is billed per 10 mg, limit $5.792, MUE 150; Q5115 is billed per 10 mg, limit $35.988, MUE 150. Report the code whose descriptor matches the product and setting in the record.

Q5119 vs Q5123: what is the difference?

Both are HCPCS Level II codes whose descriptor names rituximab. What sets Q5123 apart: biosimilar rituximab-arrx (Riabni) from Amgen Inc. Q5119 is billed per 10 mg, limit $5.792, MUE 150; Q5123 is billed per 10 mg, limit $21.083, MUE 150. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention Q5119?

4 current Billing and Coding Articles in the Medicare Coverage Database list Q5119, covering 15 states: A55639 (Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions); A56380 (Billing and Coding: Rituximab); A58582 (Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars).

What diagnosis codes support Q5119?

4 Medicare billing and coding articles list 945 covered ICD-10-CM codes for Q5119 between them, for example D59.0 (Drug-induced autoimmune hemolytic anemia); D59.11 (Warm autoimmune hemolytic anemia); D59.12 (Cold autoimmune hemolytic anemia); D59.13 (Mixed type autoimmune hemolytic anemia); D69.3 (Immune thrombocytopenic purpura). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.